Cure My Disease

Don't miss your cure!

 Log in / Sign up

Triple attack on stomach cancer: radiation, chemo, and a smart antibody

NCT ID NCT07689851

Recruiting now Disease control Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Source: ClinicalTrials.gov ↗

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This trial tests a new approach for people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. It combines standard chemotherapy (CAPOX) and radiation with an experimental drug called SHR-1701, which targets two proteins (PD-L1 and TGF-β) that help tumors hide from the immune system. The goal is to shrink tumors and improve survival, possibly making surgery an option later. The study includes about 60 adults aged 18 to 75 with HER2-negative disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
SHR-1701 (a bispecific antibody targeting PD-L1 and TGF-β)
What this could lead to
If successful, this combination could shrink tumors enough to allow surgical removal, potentially improving survival for people with advanced gastric cancer.
What could go wrong
This is an early-phase trial with only 60 participants. The treatment may cause side effects from radiation, chemotherapy, or the new drug, and it may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastric cancer gastric neoplasm gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC CANCER (GC) GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cancer Hospital Chinese Academy of Medical Sciences Shenzhen Hospital

    RECRUITING

    Shenzhen, Guangdong, China

    Contact Phone: •••-•••-••••

  • National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

    RECRUITING

    Beijing, China

    Contact Phone: •••-•••-••••

  • Shanxi Cancer Hospital

    RECRUITING

    Taiyuan, Shanxi, China

    Contact Phone: •••-•••-••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.